Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07160725) titled 'A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors' on Aug. 29.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Bristol-Myers Squibb
Condition:
Solid Tumours
Intervention:
Drug: BMS-986517
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: October 28, 2025
Target Sample Size: 315
Countries of Recruitment:
United States
Denmark
Japan
Spain
Denmark
Japan
Spain
United States
To know more, visit https...